Switch theme
Sign up to access all valuation multiples
Changchun BCHT Biotechnology Co is a biopharmaceutical enterprise specializing in the research and development, production and sales of human vaccines.
2004
n/a
LTM Revenue $177M
LTM EBITDA $50.7M
$1.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Changchun BCHT has a last 12-month revenue (LTM) of $177M and a last 12-month EBITDA of $50.7M.
In the most recent fiscal year, Changchun BCHT achieved revenue of $171M and an EBITDA of $50.2M.
Changchun BCHT expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Changchun BCHT valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $177M | XXX | $171M | XXX | XXX | XXX |
| Gross Profit | $152M | XXX | $146M | XXX | XXX | XXX |
| Gross Margin | 85% | XXX | 85% | XXX | XXX | XXX |
| EBITDA | $50.7M | XXX | $50.2M | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBIT | $36.4M | XXX | $41.7M | XXX | XXX | XXX |
| EBIT Margin | 21% | XXX | 24% | XXX | XXX | XXX |
| Net Profit | $33.0M | XXX | $32.2M | XXX | XXX | XXX |
| Net Margin | 19% | XXX | 19% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Changchun BCHT's stock price is CNY 21 (or $3).
Changchun BCHT has current market cap of CNY 8.7B (or $1.2B), and EV of CNY 8.7B (or $1.2B).
See Changchun BCHT trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.2B | $1.2B | XXX | XXX | XXX | XXX | $0.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Changchun BCHT has market cap of $1.2B and EV of $1.2B.
Changchun BCHT's trades at 7.1x EV/Revenue multiple, and 24.0x EV/EBITDA.
Equity research analysts estimate Changchun BCHT's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Changchun BCHT has a P/E ratio of 36.7x.
See valuation multiples for Changchun BCHT and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV (current) | $1.2B | XXX | $1.2B | XXX | XXX | XXX |
| EV/Revenue | 6.8x | XXX | 7.1x | XXX | XXX | XXX |
| EV/EBITDA | 23.8x | XXX | 24.0x | XXX | XXX | XXX |
| EV/EBIT | 33.1x | XXX | 28.9x | XXX | XXX | XXX |
| EV/Gross Profit | 7.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 36.7x | XXX | 37.6x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -63.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChangchun BCHT's last 12 month revenue growth is 10%
Changchun BCHT's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Changchun BCHT's rule of 40 is 46% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Changchun BCHT's rule of X is 54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Changchun BCHT and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 29% | XXX | 29% | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | -25% | XXX | XXX | XXX |
| Rule of 40 | 46% | XXX | 40% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 37% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 13% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 61% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Changchun BCHT acquired XXX companies to date.
Last acquisition by Changchun BCHT was XXXXXXXX, XXXXX XXXXX XXXXXX . Changchun BCHT acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Changchun BCHT founded? | Changchun BCHT was founded in 2004. |
| Where is Changchun BCHT headquartered? | Changchun BCHT is headquartered in China. |
| Is Changchun BCHT publicy listed? | Yes, Changchun BCHT is a public company listed on SHG. |
| What is the stock symbol of Changchun BCHT? | Changchun BCHT trades under 688276 ticker. |
| When did Changchun BCHT go public? | Changchun BCHT went public in 2021. |
| Who are competitors of Changchun BCHT? | Similar companies to Changchun BCHT include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Changchun BCHT? | Changchun BCHT's current market cap is $1.2B |
| What is the current revenue of Changchun BCHT? | Changchun BCHT's last 12 months revenue is $177M. |
| What is the current revenue growth of Changchun BCHT? | Changchun BCHT revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Changchun BCHT? | Current revenue multiple of Changchun BCHT is 6.8x. |
| Is Changchun BCHT profitable? | Yes, Changchun BCHT is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Changchun BCHT? | Changchun BCHT's last 12 months EBITDA is $50.7M. |
| What is Changchun BCHT's EBITDA margin? | Changchun BCHT's last 12 months EBITDA margin is 29%. |
| What is the current EV/EBITDA multiple of Changchun BCHT? | Current EBITDA multiple of Changchun BCHT is 23.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
